Tirtha Chakraborty
Chief Tech/Sci/R&D Officer bei VOR BIOPHARMA INC.
Vermögen: 429 190 $ am 31.03.2024
Profil
Tirtha Chakraborty is currently the Chief Scientific Officer at Vor Biopharma, Inc. since 2020 and an Advisor at Specific Biologics, Inc. since 2023.
Previously, Tirtha held the position of Executive Director & Head-Hematology at CRISPR Therapeutics AG from 2015 to 2018 and Vice President-Cell Therapy Research at Sana Biotechnology, Inc. from 2018 to 2019.
Tirtha obtained a doctorate degree from Tata Institute of Fundamental Research.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VOR BIOPHARMA, INC.
0,27% | 01.03.2024 | 181 093 ( 0,27% ) | 429 190 $ | 31.03.2024 |
Aktive Positionen von Tirtha Chakraborty
| Unternehmen | Position | Beginn |
|---|---|---|
| VOR BIOPHARMA INC. | Chief Tech/Sci/R&D Officer | 01.10.2019 |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Consultant / Advisor | 24.07.2023 |
Ehemalige bekannte Positionen von Tirtha Chakraborty
| Unternehmen | Position | Ende |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 01.10.2019 |
| CRISPR THERAPEUTICS AG | Director/Board Member | 01.10.2018 |
Ausbildung von Tirtha Chakraborty
| Tata Institute of Fundamental Research | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Vor Biopharma, Inc. | |
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
